FDA states Ozempic, Wegovy are not limited any longer, which might influence rates

The United State Fda claimed Ozempic and Wegovy prevail GLP-1 medicines for diabetes mellitus and weight management and are no more offered. CBS Information New york city contributor Ali Bauman reports whether supply adjustments might trigger customers to pay even more.